Bayer will showcase significant advancements in its radiology portfolio at the 2025 European Congress of Radiology (ECR), taking place from February 26 to March 2 in Vienna, Austria. The company will highlight key developments in contrast agents, injection systems, and artificial intelligence (AI) innovations, reinforcing its commitment to enhancing radiology practices and improving patient outcomes.
Breakthroughs in Contrast-Enhanced MRI: Gadoquatrane
A key focus of Bayer’s presence at ECR 2025 will be the latest clinical findings on gadoquatrane, an investigational macrocyclic gadolinium-based contrast agent designed for contrast-enhanced magnetic resonance imaging (MRI). Bayer will present detailed Phase III data, including late-breaking results from the pivotal QUANTI CNS study, which evaluated gadoquatrane’s efficacy and safety in central nervous system (CNS) imaging at a reduced gadolinium dose compared to standard macrocyclic GBCAs.
Key scientific sessions include:
- QUANTI CNS Phase III Study Results: Efficacy and safety of gadoquatrane in CNS contrast-enhanced MRI at a reduced gadolinium dose.
- Efficacy of Gadoquatrane: A comparative analysis of low-dose, high-relaxivity macrocyclic gadolinium-based contrast agent performance at different post-injection intervals versus gadobutrol.
These sessions will provide critical insights into gadoquatrane’s potential to enhance imaging quality while minimizing gadolinium exposure.
Advancements in CT Imaging: Centargo | Cardio
Bayer continues to push the boundaries of cardiac imaging with the introduction of Centargo | Cardio, an innovative injector package for Cardiac CT. This package integrates the MEDRAD™ Centargo CT Injection System with advanced clinical applications and patient preparation resources, allowing imaging professionals to establish optimized Cardiac CT practices tailored to their institutions.
A key presentation at ECR 2025 will highlight the results of a study conducted at the Centre d’Imagerie Médicale de Radiothérapie (CIMROD) in France, focusing on contrast consumption, efficiency, patient care, and environmental impact following regulatory changes in France’s contrast supply model.
- MEDRAD™ Centargo: Insights from the CIMROD Experiment (March 1, 2:00 pm CET)
Since receiving EU CE marking in 2020 and FDA clearance in late 2024, the MEDRAD™ Centargo CT Injection System has launched in 51 markets worldwide, offering significant operational benefits to radiology departments facing increasing imaging demands and workforce shortages.
Expanding AI Capabilities in Radiology
Recognizing AI’s transformative potential, Bayer is expanding its AI ecosystem to support radiologists in their daily clinical tasks. At ECR 2025, the company will introduce a new collaboration with Systalyze, a Massachusetts Institute of Technology (MIT) spin-off. Systalyze specializes in cloud compute optimization, and its partnership with Bayer’s AI Innovation Platform (AIIP) aims to enhance the efficiency, scalability, and sustainability of AI-driven healthcare solutions.
AIIP, built on Google Cloud technology, provides a secure, collaborative environment for developing and deploying AI and machine learning applications for medical imaging. With integrated external data providers and public datasets, AIIP streamlines the process of acquiring high-quality medical imaging data.
Additionally, Bayer will showcase case studies demonstrating the successful adoption of Calantic™ Digital Solutions, a cloud-based AI marketplace developed by radiologists for radiologists. European institutions such as Inselspital Bern, Imapôle (France), TéléDiag (France), and SERGAS (Spain) have successfully incorporated Calantic™ into their clinical workflows, enhancing efficiency and decision-making in radiology.
Other Scientific Highlights from Bayer at ECR 2025
Bayer will present a range of additional research studies and technological advancements, covering diverse aspects of radiology, including liver imaging, contrast agent safety, and AI applications in cardiovascular imaging:
- Preclinical Profile of a New Macrocyclic MRI Liver Agent (February 27, 10-11 am CET)
- Clinical Safety of Gadoxetate Disodium: A retrospective analysis of over 20 years of use, spanning nearly 12 million administrations. (Online Poster)
- New Possibilities for CT Imaging and Contrast Agents (February 26, 11:30 am CET)
- DENSE-2 Study: Evaluation of contrast-enhanced mammography and abbreviated MRI screening in women with extremely dense breasts. (February 27, 4-5:30 pm CET)
- AI in Non-Invasive Cardiovascular Imaging: A Systematic Review and Meta-analysis (Poster No. C-19973)
Bayer’s Commitment to Radiology Innovation
Table of Contents
Bayer’s presence at ECR 2025 underscores its leadership in radiology, with ongoing investments in imaging agents, cutting-edge technology, and AI solutions. Through these innovations, Bayer aims to unlock new opportunities in medical imaging, improve patient care, and support radiologists in addressing the evolving challenges of modern healthcare.
For more details on Bayer’s sessions and innovations at ECR 2025, visit the official event program or Bayer’s radiology website.
About Bayer in Radiology
As a true life-science company with a heritage of over 100 years in radiology, Bayer is committed to providing excellence – from innovative products to high-quality services – to support efficient and optimized patient care. Bayer offers a leading portfolio of contrast media for computed tomography (CT), X-ray, and magnetic resonance imaging (MRI), along with devices for their precise administration, informatics solutions, and a medical imaging platform delivering access to applications, including those enabled by AI. Bayer’s radiology products generated about €2bn sales in 2023.
About Bayer
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, “Health for all, Hunger for none,” the company’s products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses.
At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2023, the Group employed around 100,000 people and had sales of 47.6 billion euros. R&D expenses before special items amounted to 5.8 billion euros. For more information, go to www.bayer.com.
